MARKET ACCESS 201

Advances in precision medicines, cell and gene therapies, drugs for rare diseases and medical technologies over the past few years have brought great promise to patients and their families in Canada. Recognizing that these therapies will become more prevalent in the future, all levels of the healthcare system are starting to focus their priorities on being “future ready” and ensuring the processes are in place to make decisions on novel treatments. Hear from key speakers and stakeholders as they give updates on their organizations and how they are adapting to this new reality.

AGENDA

8:30am
Welcome & Housekeeping
EMCEE John-Paul Dowson, PDCI

8:45am
Pharmaceutical Policy Update

Speakers from Canada’s two Health Technology Assessment Agencies will walk through updates on activities currently underway at each agency. They will highlight the priorities for INESSS and CADTH and what can be expected for the remainder of 2023 into 2024.

• Daniel Macdonald, Health Canada
• Neelam Merchant, Health Canada

Moderated by Rebecca Vieira,Vertex Pharmaceuticals

9:45am
pCPA – An update on the evolution of the PCPA

With a new CEO in place, the pCPA and industry face unprecedented changes in our market access environment. Having evolved from a small office supporting provinces’ negotiations, to a new stand alone corporate organization, the pCPA must now pivot and renew its focus on the future. With an entirely new structure, the organization is facing a growing list of products waiting for negotiations; and it has the enormous task of building a renewed negotiation structure that can accommodate an entirely new paradigm in biopharemaceutical care and reimbursement (cell/gene therapies, etc). Join our panelists as they discuss how we arrived here; what’s in store for the future; and how biopharmaceutical companies can effectively work with a new pCPA.

• Doug Clark, pCPA

Moderated by John-Paul Dowson, PDCI

10:45am
Networking Break

11:15am
Panel – Equity in Access

Equity in Healthcare is a hot topic that all levels of government, industry and patient organizations are trying to better understand and tackle. The definition of equity in healthcare can mean different things to different people. This panel will give real life examples of challenges in equity that the panelists have faced and how they have worked to overcome these barriers by building bespoke solutions. 

• Ned Pojskic, GreenShield
• Stephen Piazza, Canadian Cancer Society
• Lanre Punji-Ajayi, Sickle Cell Awareness Group of Ontario (SCAGO)

Moderated by Christina Cunningham, Vertex Pharmaceuticals

12:00nn
Lunch & Networking

1:00pm TBA

1:45pm
Update on the Drug Shortage Issue

Drug shortages have been an ongoing issue that has created difficulties for both patients, healthcare practitioners and across the distribution channels.  In response, Health Canada has been working with stakeholders such as federal, provincial, and territorial governments, and health professional, patient, and industry associations to share information and to identify actions to prevent and mitigate drug shortages in Canada. Stephanie Di Trapani, Director of Health Canada’s Drug Shortages Division will be providing an update on Canada’s drug shortages situation and the initiatives that are currently being undertaken to improve the current and future situation.

• Stephanie Di Trapani, Drug Shortage Division, Health Canada

Moderated by Mark Omoto

2:15pm
Networking Break

2:45pm
Canadian HTA

• Brent Fraser, CADTH

Moderated by Rebecca Vieira, Vertex Pharmaceuticals

3:45pm
Closing Remarks

4:00pm
Networking Reception - Meet the CAHR Board!

Please note: if you're working towards your CMAP Certification you 
MUST attend both Market Access 201 and Market Access 101.

Upon completion. you will be able to:

• Explain why market access is critical to commercial success
• Describe the market access players in the public and private payer environments
• Discuss how review processes, pricing and regulations impact public and private payer environments
• Find the information necessary to understand public and private submission processes
• Identify key players in the market access and reimbursement environments
• Discuss the intricacies of bringing a new drug to market in Canada
• Identify the key approvals pathways, processes and agencies involved in bringing a new drug to market in Canada
• Leverage a solid foundation in all areas of Patient Support Programs in Canada

Limited number of special discounts available to patient groups and students. Please contact the CAHR office for information.

THANK YOU TO OUR PARTNERS

		GOLD
		SILVER
		BRONZE

CAHR reserves the right to cancel or change speakers, content and date without prior notice. We assume no liability for these changes.

Cancellation Policy: For cancellations two (2) weeks or more in advance, delegates will receive a 75% refund. For cancellations made less than two (2) weeks in advance, no refunds are given. Delegate substitutions will be accepted at no cost.